DV
Dividend Vision

CRNX — Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (CRNX)

Total return is 245.6% over the past 8.1 years, 33.6 points ahead of SPY at 212.0%. Its deepest 1-year drawdown was 42.2%.

CRNX is a healthcare equity stock that trades as an individual security rather than a diversified ETF fund. The holding does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular dividend payments. This healthcare company appeals primarily to growth-oriented investors seeking capital appreciation exposure to the pharmaceutical sector.

CRNX key facts

Asset type
Stock
Asset class
Equity
Inception date
07/18/2018
Distribution frequency
None
Last close
$84.70
Market cap
$8,986,263,552
Average volume
2279100.0
Beta
0.088
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.05